Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia.
Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia.
复制标题
DOI：
10.1111/dom.14415
复制
发表时间：
2021-08
期刊：
影响因子：
--
通讯作者：
Johansen OE
中科院分区：
文献类型：
--
作者：
Ji Q;Ji L;Mu Y;Zhao J;Zinman B;Wanner C;George JT;Zwiener I;Ueki K;Yokote K;Ogawa W;Johansen OE
研究包括亚洲人在内的已确诊心血管（CV）疾病的2型糖尿病患者的体重指数（BMI）是否影响钠-葡萄糖共转运蛋白- 2抑制剂恩格列净的心肾益处。在EMPA‐REG OUTCOME试验的探索性分析中，我们使用Cox回归来评估依帕列净对全因死亡率、心力衰竭（HHF）或CV死亡住院以及基线BMI类别肾病的发生或恶化的影响。在7020名参与者中（1517名亚洲人[21.6%]），934名（13.3%）、2465名（35.1%）和3621名（51.6%）的BMI分别小于25、25至小于30和30 kg/m2或更高。总体而言，恩格列净与安慰剂在全因死亡率、HHF或CV死亡以及肾病发生或恶化方面的风险比分别为0.68 （95% CI 0.57, 0.82）、0.66（0.55,0.79）和0.61(0.53,0.70)，并且在BMI类别中是一致的(治疗与BMI之间相互作用的P值为。6772年,。3087和。6265年,分别)。亚洲人使用这些BMI分类和低于24,24至低于28,28kg /m2或更高类别的结果相似。依帕列净降低了心肾和死亡风险，无论基线BMI如何，包括BMI较低的亚洲人。
To investigate whether the cardiorenal benefits of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin are affected by body mass index (BMI) in type 2 diabetes patients with established cardiovascular (CV) disease, including Asians. In this exploratory analysis of the EMPA‐REG OUTCOME trial, we used Cox regression to evaluate the effects of empagliflozin on all‐cause mortality, hospitalization for heart failure (HHF) or CV death, and incident or worsening nephropathy by baseline BMI category. Of the 7020 participants (1517 Asians [21.6%]), 934 (13.3%), 2465 (35.1%) and 3621 (51.6%) had a BMI of less than 25, 25 to less than 30, and 30 kg/m2 or higher, respectively. Overall, hazard ratios for empagliflozin versus placebo for all‐cause mortality, HHF or CV death, and incident or worsening nephropathy were 0.68 (95% CI 0.57, 0.82), 0.66 (0.55, 0.79) and 0.61 (0.53, 0.70), respectively, and were consistent across BMI categories (P values for interaction between treatment and BMI were .6772, .3087 and .6265, respectively). Results were similar in Asians using these BMI categories and categories of less than 24, 24 to less than 28, and 28 kg/m2 or higher. Empagliflozin reduced cardiorenal and mortality risk regardless of BMI at baseline, including in Asians with a lower BMI.
登录
查看更多内容
影响因子：
5.8
作者：
Ohkuma, Toshiaki;Van Gaal, Luc;Neal, Bruce
通讯作者：
Neal, Bruce
DOI：
10.1056/nejmoa1304501
发表时间：
2014-01-16
期刊：
The New England journal of medicine
影响因子：
--
作者：
Tobias DK;Pan A;Jackson CL;O'Reilly EJ;Ding EL;Willett WC;Manson JE;Hu FB
通讯作者：
Hu FB
影响因子：
5.2
作者：
Ma RC;Chan JC
通讯作者：
Chan JC
DOI：
10.1111/j.1749-6632.2012.06838.x
发表时间：
2013-01-01
期刊：
YEAR IN DIABETES AND OBESITY
影响因子：
--
作者：
Gujral, Unjali P.;Pradeepa, R.;Mohan, V.
通讯作者：
Mohan, V.
影响因子：
16.2
作者：
Edqvist, Jon;Rawshani, Araz;Rosengren, Annika
通讯作者：
Rosengren, Annika